Skip to content

Price / book at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
Arrowhead Research logo
Arrowhead ResearchARWR
14.3×+11.7×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
6.9×+2.0×
Scholar Rock logo
Scholar RockSRRK
20.5×+10.7×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-0.7×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
3.3×+1.5×

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s price / book?
Dyne Therapeutics, Inc. (DYN) reported price / book of 3.5× in Q1 2026.
How has Dyne Therapeutics, Inc.'s price / book changed year-over-year?
Dyne Therapeutics, Inc.'s price / book increased by 95.5% year-over-year, from 1.8× to 3.5×.
What is the long-term trend for Dyne Therapeutics, Inc.'s price / book?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s price / book has grown at a 1.8% compound annual growth rate (CAGR), from 3× to 3.3×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.